Patents by Inventor Michael C. WEI

Michael C. WEI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATMENT OF PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE
    Publication number: 20240043553
    Abstract: The present invention relates to the treatment of subjects having previously untreated follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having previously untreated FL by administering a combination of mosunetuzumab and lenalidomide.
    Type: Application
    Filed: June 21, 2023
    Publication date: February 8, 2024
    Inventors: Andrea KNAPP, Chi-Chung LI, Enkhtsetseg PUREV, Michael C. WEI
  • METHODS FOR TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE
    Publication number: 20230190932
    Abstract: The present invention relates to the treatment of subjects having relapsed and/or refractory (R/R) follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having R/R FL by administering a combination of mosunetuzumab and lenalidomide.
    Type: Application
    Filed: October 28, 2022
    Publication date: June 22, 2023
    Inventors: Catherine GRANIER, Andrea Knapp, Chi-Chung Li, Carol Elaine O'Hear, Enkhtsetseg Purev, Michael C. Wei
  • DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES AND ANTI-CD79B ANTIBODY DRUG CONJUGATES
    Publication number: 20220153842
    Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.
    Type: Application
    Filed: November 2, 2021
    Publication date: May 19, 2022
    Inventors: Chi-Chung LI, Carol Elaine O'HEAR, Stephen James SIMKO, III, Iris Tranthuyngan TO, Klara TOTPAL, Hong WANG, Michael C. WEI, Shen YIN, Brendan Christian BENDER, Xi CHEN, Yu-Waye CHU, Maria HRISTOPOULOS